In this study, we assessed the expression of HIF-1α and other markers of hypoxia and angiogenesis including VEGF, vascular endothelial growth factor receptor 3 (VEGFR3), and microvessel density (MVD) in TNBC as compared to HER2+ and luminal-type breast cancers in order to evaluate the practical potential of using anti-HIF-1α as a therapeutic target for TNBC preferentially to other breast cancer subtypes. The gene discussed is FLT4; the disease is breast carcinoma.